The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | CANDOR: KdD is a new regimen for R/R MM
Saad Usmani, MD, FACP, Levine Cancer Institute, Charlotte, NC, discusses the rationale and results from the primary analysis of CANDOR (NCT03158688), a multicenter, phase III randomized study comparing carfilzomib, dexamethasone and daratumumab (KdD) vs. carfilzomib and dexamethasone (Kd) in relapsed/refractory (R/R) multiple myeloma (MM). This study demonstrated that KdD resulted in a favorable efficacy, was generally well tolerated and represents an efficacious new regimen for R/R MM. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
